Disease milestones development risk ↑ and survival ↓ [46]; level of CSF amyloid-β and amyloid-β/total-tau ratio↓ and whole brain atrophy ↑ [4]; MCI ↑, orthostatic hypotension ↑, RBD ↑ and rapid progression [43] in diffuse malignant subtype. This evidence concerns the gene MAPT and Brain atrophy.